老年早期乳腺癌全身治疗考量:综述
该综述回顾了支持老年早期乳腺癌患者全身治疗的现有证据,涵盖细胞毒性化疗、降阶梯方案及靶向治疗的数据缺口,并介绍了优化决策与支持治疗的工具。文章强调应避免过度治疗与治疗不足,并指出正在进行的临床试验旨在优化该人群的医疗照护。
要点
- 老年早期乳腺癌全身治疗需权衡复发风险与治疗毒性。
- 激素受体阳性疾病可考虑辅助CDK4/6抑制剂,三阴性乳腺癌可考虑新辅助帕博利珠单抗。
- 应避免低风险癌症或高毒性风险患者的过度治疗,也应避免高风险癌症的治疗不足。
核心结论
- 临床医生应利用现有数据和决策工具,为老年早期乳腺癌患者提供最佳实践治疗。
- 避免过度治疗和治疗不足是优化老年早期乳腺癌全身治疗的关键。
研究设计与样本
- 综述文章,回顾支持老年早期乳腺癌全身治疗的现有证据,并介绍决策与支持治疗工具。
主要发现
- 老年人在治疗性临床试验中代表性不足,但支持各亚型早期乳腺癌优化管理的证据不断增加。
- 激素受体阳性疾病中辅助CDK4/6抑制剂和三阴性乳腺癌中新辅助帕博利珠单抗是新型策略。
- 现有证据支持考虑细胞毒性化疗、降阶梯方案和靶向治疗的数据缺口。
临床怎么用
- 当现有证据表明较低强度方案可能足以应对较低风险癌症,和/或患者化疗严重毒性风险高时,应避免过度治疗。
- 对于较高风险癌症的老年患者,不考虑潜在不利因素的治疗不足可能增加乳腺癌相关死亡率。
- 使用决策工具和支持治疗工具优化老年早期乳腺癌患者的照护。
局限性
- 老年人在治疗性临床试验中持续代表性不足。
- 细胞毒性化疗、降阶梯方案和靶向治疗在老年人群中的数据存在缺口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The treatment of older adults with chemotherapy for early-stage breast cancer involves a complex decision-making process that weighs the competing risks of disease recurrence against the potential harms of treatment. While older adults continue to be underrepresented in therapeutic clinical trials, there is a growing body of evidence to support optimal management of each subtype of early-stage breast cancer, including novel strategies like adjuvant cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive disease, and the neoadjuvant use of pembrolizumab in triple-negative breast cancer. OBSERVATIONS: The available evidence to support the systemic management of early-stage breast cancer in older adults with consideration of the data gaps for cytotoxic chemotherapy, de-escalated regimens, and targeted therapies is reviewed, and tools to optimize decision-making and supportive care for older adults with early breast cancer are presented. Clinicians should aim to avoid overtreatment when available evidence suggests a less intensive approach may suffice for a lower-risk cancer, and/or the patient is at high risk of serious toxic effects from chemotherapy treatment. On the other hand, undertreatment without consideration of the potential downsides may increase breast cancer-related mortality in older patients with higher-risk cancers. CONCLUSIONS AND RELEVANCE: This review will help clinicians best use the available data and decision-making tools to support best practice for treating older adults with early-stage breast cancer and will highlight ongoing clinical trials aimed at optimizing medical care for this patient population.
引用
- Smith CE, Sammons SL, Minami CA, et al. Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review. JAMA Oncol. 2026. PMID: 42658515. doi:10.1001/jamaoncol.2026.3121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。